Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research

    Dr. Jingxuan Zhang is the Doctor of Veterinary Medicine in Preventive Veterinary Medicine of China Agricultural University, master of Pharmacology and Toxicology of Shanghai  Pharmaceutical Industry Research Institute - National Shanghai New Drug Safety Evaluation Research Center, bachelor of Clinical Medicine of Tongji University School of Medicine in Shanghai.  Dr. Zhang is also the new drug review expert of CDE (Center for Drug Evaluation, NMPA), Chinese certified toxicologist, Chinese veterinary pathologist, member of the Toxicological Pathology Professional Committee of the Chinese Pharmaceutical Association and Chinese Society of Toxicology, director of the Veterinary Pathology of the Chinese Society of Animal Science and Veterinary Medicine, executive director of Drug Clinical Evaluation of China Medical Association of Minorities and director of the Women and Pediatric Immunology of the China Healthy Birth Science Association.

    Dr. Zhang has a solid industry foundation, research skills and outstanding leadership in the pharmaceutical industry, especially in the fields of drug toxicology, preclinical safety evaluation, and clinical medicine.  Dr. Zhang has 13 years of study and work experience in the preclinical safety evaluation of new drugs in the GLP centers. She is familiar with and understands the preclinical safety evaluation processes and operations, as well as the operation management of the GLP laboratory.  In addition, Dr. Zhang also has 10 years of working experience as a full-time professional leader of toxicological pathology and study director of drug toxicology in GLP centers.  She is proficient in the implementation and operation management of toxicology tests, with rich experience in diagnosis of toxicological pathology/experimental animal pathology and laboratory management.  Dr. Zhang completed more than 200 studies of pathological diagnosis and presided over 2 carcinogenicity studies.  Furthermore, she has experience for nearly 6 years in full-time pharmacologic pathological diagnosis and traditional Chinese medicine toxicology research, and for 4 years in clinical diagnosis and treatment.  In 2010, Dr. Zhang Jingxuan has passed the examinations and were qualified as  chinese certified Toxicologist and chinese veterinary pathologist from the Chinese Society of Toxicology and the Chinese Society of Animal Science and Veterinary Medicine respectively.  Moreover, Dr. Zhang has high academic attainments and participated in a number of scientific research projects of the National Natural Science Foundation of China, the National Science and Technology Major Project and the National Key R&D Program of China.  She has published many papers and participated in the editing and publication of many academic works.

    Prior joining Medicilon, Dr. Zhang worked in Beijing University of Chinese Medicine, Beijing Union-Genius Pharmaceutical Technology Co.,Ltd., National Shanghai New Drug Safety Evaluation Research Center, and Joinn Laboratories (China) Co., Ltd.  Her career has accumulated a wealth of practical experience in drug development and team management for her.

    Dr. Zhang said, "I am honored to join such a professional and innovative team as Medicilon. I hope to use my professional background and management experience in the field of drug research and development, and work together with the company's strong research and development management team to speed up the process of new drug research and development, so that more innovative and safety new drug will enter the clinic as soon as possible!"

    Dr. Chunlin Chen, Founder and CEO of Medicilon, mentioned, "Medicilon is in a stage of rapid development, and we welcome the addition of Dr. Jingxuan Zhang during this critical period.  Dr. Zhang has extensive medical knowledge, profound attainments in the field of drug toxicology, and outstanding achievements.  We believe that the addition of Dr. Zhang will further enhance the company's global preclinical R&D service capabilities and scale, and better empower the global clients!"